Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants

View ORCID ProfileFanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Lingling Yu, Yuxue Gao, Na Zhang, Yao Wang, Fei Shao, Xiaohua Hao, Yanli Xu, Ronghua Jin, Youchun Wang, Xiaoliang Sunney Xie, Yunlong Cao
doi: https://doi.org/10.1101/2022.08.09.503384
Fanchong Jian
1Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China
2College of Chemistry and Molecular Engineering, Peking University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fanchong Jian
Yuanling Yu
3Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiliang Song
1Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China
4School of Life Sciences, Peking University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ayijiang Yisimayi
1Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China
4School of Life Sciences, Peking University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingling Yu
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuxue Gao
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Na Zhang
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao Wang
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Shao
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaohua Hao
7Beijing Ditan Hospital, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanli Xu
7Beijing Ditan Hospital, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronghua Jin
7Beijing Ditan Hospital, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youchun Wang
3Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoliang Sunney Xie
1Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sunneyxie@biopic.pku.edu.cn yunlongcao@pku.edu.cn
Yunlong Cao
1Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P.R. China
5Changping Laboratory, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sunneyxie@biopic.pku.edu.cn yunlongcao@pku.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Multiple BA.4 and BA.5 subvariants with R346 mutations on the spike glycoprotein have been identified in various countries, such as BA.4.6/BF.7 harboring R346T, BA.4.7 harboring R346S, and BA.5.9 harboring R346I. These subvariants, especially BA.4.6, exhibit substantial growth advantages compared to BA.4/BA.5. In this study, we showed that BA.4.6, BA.4.7, and BA.5.9 displayed higher humoral immunity evasion capability than BA.4/BA.5, causing 1.5 to 1.9-fold decrease in NT50 of the plasma from BA.1 and BA.2 breakthrough-infection convalescents compared to BA.4/BA.5. Importantly, plasma from BA.5 breakthrough-infection convalescents also exhibits significant neutralization activity decrease against BA.4.6, BA.4.7, and BA.5.9 than BA.4/BA.5, showing on average 2.4 to 2.6-fold decrease in NT50. For neutralizing antibody drugs, Bebtelovimab remains potent, while Evusheld is completely escaped by these subvariants. Together, our results rationalize the prevailing advantages of the R346 mutated BA.4/BA.5 subvariants and urge the close monitoring of these mutants, which could lead to the next wave of the pandemic.

Competing Interest Statement

X.S.X. and Y.C. are founders of Singlomics Biopharmaceuticals. Other authors declare no competing interests.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 10, 2022.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
Fanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Lingling Yu, Yuxue Gao, Na Zhang, Yao Wang, Fei Shao, Xiaohua Hao, Yanli Xu, Ronghua Jin, Youchun Wang, Xiaoliang Sunney Xie, Yunlong Cao
bioRxiv 2022.08.09.503384; doi: https://doi.org/10.1101/2022.08.09.503384
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
Fanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Lingling Yu, Yuxue Gao, Na Zhang, Yao Wang, Fei Shao, Xiaohua Hao, Yanli Xu, Ronghua Jin, Youchun Wang, Xiaoliang Sunney Xie, Yunlong Cao
bioRxiv 2022.08.09.503384; doi: https://doi.org/10.1101/2022.08.09.503384

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Immunology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4675)
  • Biochemistry (10347)
  • Bioengineering (7659)
  • Bioinformatics (26307)
  • Biophysics (13505)
  • Cancer Biology (10672)
  • Cell Biology (15424)
  • Clinical Trials (138)
  • Developmental Biology (8490)
  • Ecology (12808)
  • Epidemiology (2067)
  • Evolutionary Biology (16835)
  • Genetics (11383)
  • Genomics (15471)
  • Immunology (10603)
  • Microbiology (25186)
  • Molecular Biology (10211)
  • Neuroscience (54399)
  • Paleontology (400)
  • Pathology (1667)
  • Pharmacology and Toxicology (2889)
  • Physiology (4334)
  • Plant Biology (9237)
  • Scientific Communication and Education (1586)
  • Synthetic Biology (2556)
  • Systems Biology (6774)
  • Zoology (1461)